At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
pembrolizumab, paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating pembrolizumab, paclitaxel for Small Cell Lung Cancer. Completed, enrolled 26 participants across 1 site.
Detailed Summary
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionDec 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedSep 16, 2015
Enrollment StartSep 1, 2015
Primary CompletionDec 1, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.8 years ago
Interventions
pembrolizumab, paclitaxeldrug
pembrolizumab, paclitaxel